Clinical trials: High-Risk Oral Precancerous Disease
Leukemia, Leukemia, Myeloid
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk myelodysplastic syndrome…
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia
- Trial name
- NCT06501196
- Testing
- BH-30236, Venetoclax
- Where
- 13 sites in United States
- Volunteers
- 170 people
- Sponsor
- BlossomHill Therapeutics
Mouth Diseases
Evaluation of Oral Potentially Malignant Disorders (OPMDs) with STRATICYTE™
The purpose of this study is to validate the ability of the STRATICYTE™ predictive model to predict the transformation of oral potentially malignant disorders (OPMDs) to oral squamous cell carcinoma (OSCC) in a retrospective…
- Trial name
- NCT05853783
- Testing
- STRATICYTE™ Test
- Where
- 5 sites in United States
- Volunteers
- 180 people
- Sponsor
- Proteocyte Diagnostics Inc.
Oral Neoplasm
Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment
The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral…
- Trial name
- NCT04622462
- Testing
- Standard of Care Histopathology, STRATICYTE Assessment
- Where
- 3 sites in Canada
- Volunteers
- 500 people
- Sponsor
- Proteocyte Diagnostics Inc.